Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease

Table 1 Clinical data of the study population

	UC	CD
Number of subjects	27	11
Gender (female/male)	15/12	3/8
Age (yr, mean)	42.5 (21-66)	34.6 (21-70)
Disease duration (yr, mean)	9.3 (0-38)	5.6 (0-18)
Extent of disease:
Colon	91	8
Left side colitis	14	-
Proctitis	4	-
Ileocolitis	-	1
Prior surgery	1	1
Treatment at inclusion:
No treatment	7	4
5-ASA (topical/systemic)	19	4
Azathioprine	1	1
Prednisone (topical/systemic)	5	-
Metronidazole	-	1

¹Extensive colitis means disease extending from proximal to the splenic flexure.